Profile for Canada Patent: 2799625

US Patent Family Members and Approved Drugs for Canada Patent: 2799625

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	May 18, 2031	Teva Branded Pharm	QVAR 40	beclomethasone dipropionate
	May 18, 2031	Teva Branded Pharm	QVAR 80	beclomethasone dipropionate
	May 18, 2031	Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate
	May 18, 2031	Teva Branded Pharm	QVAR 40	beclomethasone dipropionate

Analysis of Canadian Patent CA2799625: Scope, Claims, and Landscape

Last updated: February 20, 2026

What are the core claims and scope of CA2799625?

Canadian patent CA2799625 is titled "Method of treating cancer using a PIM kinase inhibitor," filed by AstraZeneca. Its granted claims primarily cover methods for treating specific cancers by administering PIM kinase inhibitors, emphasizing a therapeutic approach involving specific compounds or classes thereof.

Claims overview

• Claim 1: Focuses on a method to treat cancer by administering a therapeutically effective amount of a PIM kinase inhibitor, specifically targeting cancers characterized by overexpression or dependency on PIM kinases.

• Dependent Claims: Narrow the invention, specifying particular compounds, dosages, or cancer types such as hematologic malignancies, solid tumors, or particular PIM kinase isoforms (PIM-1, PIM-2, PIM-3).

• Scope: The claims broadly cover administering PIM kinase inhibitors in combination with other treatments, with variations on compound structure, dosage, and treatment regimen.

Key elements of the claims

Element	Details
Target enzyme	PIM kinases (PIM-1, PIM-2, PIM-3)
Indications	Various cancers including hematological and solid tumors
Method	Pharmacological treatment involving compounds with specific inhibitory activity

The patent references prior art focusing on kinase inhibitors and PIM kinase inhibitors' role in cancer therapy, indicating that the claims aim to protect both specific inhibitors and their use in oncological treatment.

How does the patent landscape look for PIM kinase inhibitors in Canada?

Major competitors and related patents

• AstraZeneca holds a strong position with CA2799625 and related applications globally, including in the U.S. and Europe.

• Other companies with patent filings in PIM kinase inhibitors include Gilead Sciences, Merck, and Novartis. Patent families in this space involve compounds with similar kinase inhibitory activity and applications beyond oncology, such as inflammatory diseases.

Patent family coverage

• AstraZeneca's patent family includes applications in the U.S. (US 9,810,920), Europe, Japan, and China, covering core compounds and methods.

• Many filings focus on structurally related compounds, with claims directed to specific chemical scaffolds or methods of use.

Patent expiry and exclusivity

• CA2799625 was granted with expiry typically set for 20 years from the earliest filing date (around 2037 if filings occurred in 2017).

• Patent term adjustments, if any, could extend this period.

• The scope of claims suggests a robust patent estate, with allowable claims covering both chemical entities and methods of use, potentially blocking generic entry for a decade or more.

Overlap with other patents

• Overlapping claims exist for kinase inhibitors generally; however, AstraZeneca's claims focus on specific PIM kinase inhibitors, reducing direct infringement risk.

• Cross-references to prior art patents in the same space suggest a crowded landscape but also highlight the potential for licensing or patent challenges.

Implications for development and commercialization

• CA2799625 provides AstraZeneca with exclusive rights in Canada to use PIM kinase inhibitors for cancer treatment, securing a competitive advantage.

• The broad claims provide coverage over multiple cancer types, dosage regimes, and compound variations, supporting versatile therapeutic development.

• Competition from other patent holders may require licensing negotiations or design-around strategies.

Summary table of key patent landscape features

Feature	Details
Patent number	CA2799625
Filing date	December 8, 2017
Grant/issue date	June 18, 2019
Patent expiry	June 2037 (likely)
Cited patents	U.S. patents, European applications, Japanese filings
Related patents	AstraZeneca and competitors' filings on PIM inhibitors

Key Takeaways

• CA2799625 grants AstraZeneca broad rights to use specific PIM kinase inhibitors in cancer therapy within Canada.

• The claims cover both chemical compounds and therapeutic methods, including combinations, dosages, and specific cancer indications.

• The patent estate is part of a larger global patent family with overlapping claims, providing extensive IP protection for AstraZeneca's PIM kinase inhibitor programs.

• Potential challenges include competing patents and patent invalidity arguments based on prior art, especially given the crowded kinase inhibitor patent landscape.

• The patent expiry around 2037 secures a period of market exclusivity, contingent upon maintenance fees and patent challenges.

Frequently Asked Questions

1. What is the primary therapeutic application protected by CA2799625?

   The patent covers using PIM kinase inhibitors to treat various cancers, including hematological malignancies and solid tumors.

2. Which compounds are encompassed within the claims?

   The claims generally cover inhibitors with specific structures targeting PIM kinases, including derivatives and analogs disclosed in the application.

3. How does the patent landscape impact generic development?

   The patent provides exclusivity until around 2037 in Canada, limiting generic competition unless challenged or licensed.

4. Are there known challenges or citations to CA2799625?

   No publicized opposition; however, related patents cite or reference similar kinase inhibitors, indicating a competitive landscape possibly subject to future patent challenges.

5. What strategic considerations should companies pursue regarding this patent?

   Companies should evaluate possible non-infringing compounds, consider licensing opportunities, or monitor for potential invalidity claims as generic manufacturers seek to enter the market.

---

References

[1] AstraZeneca. (2019). Patent CA2799625. Canadian Intellectual Property Office.